C08L1/28

Carboxymethyl cellulose-based films and edible food casings made therefrom
09796833 · 2017-10-24 · ·

An edible film useful for applying a flavoring additive to a food item is disclosed. The edible film generally includes an edible carboxymethyl cellulose film-forming resin and an edible plasticizer. The carboxymethyl cellulose film-forming resin is preferably a blend of two different carboxymethyl celluloses having different molecular weights. The edible film preferably includes additional additives, for example an edible surfactant and an edible tackifier. The edible film can suitably accept a food flavoring ingredient to form a flavored film that can be used to apply a flavor to a food item.

Nanogels for delayed gelation

The instant application relates to nanogels or compositions that hold multivalent metal ions until some level of nanogel degradation has occurred, then slowly release the multivalent metal ions for gelation with carboxylate containing polymers. Compositions comprising such nanogels, together with polymers that can be crosslinked with multivalent metal ions, allow the deployment of such mixtures in various applications, and greatly increased gelation times.

AQUEOUS ETHYLCELLULOSE DISPERSIONS With polymeric additive

Provided is an aqueous composition having pH of 8 or higher and comprising (a) a solid phase comprising dispersed particles that comprise an amount of ethylcellulose polymer, (b) an amount of one or more polymeric dispersants, wherein said polymeric dispersant has a weight-average molecular weight of 5,000 daltons or higher, and wherein said polymeric dispersant has an acid value of 60 to 190 mg KOH/g of polymer. Also provided is a method of making such a composition using an extruder. Also provided is a film made by removing water from such a composition.

AQUEOUS ETHYLCELLULOSE DISPERSIONS With polymeric additive

Provided is an aqueous composition having pH of 8 or higher and comprising (a) a solid phase comprising dispersed particles that comprise an amount of ethylcellulose polymer, (b) an amount of one or more polymeric dispersants, wherein said polymeric dispersant has a weight-average molecular weight of 5,000 daltons or higher, and wherein said polymeric dispersant has an acid value of 60 to 190 mg KOH/g of polymer. Also provided is a method of making such a composition using an extruder. Also provided is a film made by removing water from such a composition.

AQUEOUS ETHYLCELLULOSE DISPERSIONS With polymeric additive

Provided is an aqueous composition having pH of 8 or higher and comprising (a) a solid phase comprising dispersed particles that comprise an amount of ethylcellulose polymer, (b) an amount of one or more polymeric dispersants, wherein said polymeric dispersant has a weight-average molecular weight of 5,000 daltons or higher, and wherein said polymeric dispersant has an acid value of 60 to 190 mg KOH/g of polymer. Also provided is a method of making such a composition using an extruder. Also provided is a film made by removing water from such a composition.

A SUSTAINED RELEASE COMPOSITION COMPRISING A METHYLCELLULOSE
20220047498 · 2022-02-17 ·

A sustained release composition for oral administration comprises a physiologically active ingredient mixed with a methylcellulose, wherein the methylcellulose has anhydroglucose units joined by 1-4 linkages and wherein hydroxy groups of anhydroglucose units are substituted with methyl groups such that the s23/s26 is more than 0.27, and wherein the concentration of methylcellulose is from 0.1 to 10% by dry weight of the active ingredient.

SUPPORT MATERIAL, SUPPORT MATERIAL POWDER, AND METHOD FOR PRODUCING THREE-DIMENSIONAL OBJECT USING SAME

A support material contains at least one member selected from the group consisting of low molecular weight saccharides, polyvinyl alcohols, and polyalkylene glycols; non-water-soluble cellulose fibers; and a water-soluble cellulose derivative.

Cellulose composite

[Problem] The present invention addresses the problem of providing a cellulose composite whereby the cellulose composite itself disperses stably even when ions are blended in a high concentration in a beverage, and also has excellent suspension stability. [Solution] A cellulose composite comprising cellulose, an anionic polysaccharide not having a chemically crosslinked structure, and water-absorbent particles comprising a compound having a chemically crosslinked structure wherein the cellulose composite has a viscosity of 10 mPa.Math.s or higher when 1 mass % of the cellulose composite is dispersed in an aqueous solution in which 0.45 g of sodium bicarbonate is dissolved in 100 mL of pure water.

Treatment of rhinosinusitis with P-glycoprotein inhibitors

Provided herein are, inter alia, methods for treating rhinosinusitis with P-glycoprotein inhibitors. A subject having rhinosinusitis is identified and then treated by administration to the subject an effective amount of a P-gp inhibitor. The subject having rhinosinusitis can be identified by one of skill in the art based on known methods, e.g., based on detection of the presence of symptoms, by endoscopy, or by computed tomography. The efficacy of the treatment can be monitored by methods known in the art, e.g., by monitoring symptoms, by endoscopy or computed tomography. The P-glycoprotein inhibitor can be delivered to the subject's nasal passage and sinuses by an inhalation device, by flushing, by spraying, or by an eluting implant surgically placed in the subject's nasal passage or sinuses. The P-glycoprotein inhibitor can also be administered in combination with a corticosteroid.

Treatment of rhinosinusitis with P-glycoprotein inhibitors

Provided herein are, inter alia, methods for treating rhinosinusitis with P-glycoprotein inhibitors. A subject having rhinosinusitis is identified and then treated by administration to the subject an effective amount of a P-gp inhibitor. The subject having rhinosinusitis can be identified by one of skill in the art based on known methods, e.g., based on detection of the presence of symptoms, by endoscopy, or by computed tomography. The efficacy of the treatment can be monitored by methods known in the art, e.g., by monitoring symptoms, by endoscopy or computed tomography. The P-glycoprotein inhibitor can be delivered to the subject's nasal passage and sinuses by an inhalation device, by flushing, by spraying, or by an eluting implant surgically placed in the subject's nasal passage or sinuses. The P-glycoprotein inhibitor can also be administered in combination with a corticosteroid.